Compare CRDF & AURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDF | AURE |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | Hong Kong |
| Employees | N/A | 4 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.8M | 80.2M |
| IPO Year | 2012 | N/A |
| Metric | CRDF | AURE |
|---|---|---|
| Price | $1.32 | $1.83 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.63 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 20.8K |
| Earning Date | 05-07-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $365,993.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $1.16 | $0.18 |
| 52 Week High | $4.56 | $3.53 |
| Indicator | CRDF | AURE |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 22.65 |
| Support Level | $1.18 | $0.29 |
| Resistance Level | $1.66 | $2.67 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 52.17 | 14.03 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
Aurelion Inc is a Tether Gold (XAUT) Real World Asset (RWA) company focused on developing a business around tokenized gold. XAUT combines the stability of physical gold with the efficiency of blockchain, providing investors access to a tokenized gold reserve that could serve as a haven to inflation, currency devaluation, and crypto volatility. In parallel to building a business around the development of tokenized gold, Aurelion provides wealth management and asset management services.